Levemir (insulin detemir rDNA origin) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 62 Diseases   26 Trials   26 Trials   826 News 
30 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Levemir (insulin detemir rDNA origin) / Novo Nordisk
2004-003887-31: \"Farmakodynamiske egenskaber af to langtidsvirkende insulinanaloger i sammenligning med NPH insulin\"

Ongoing
4
12
Europe
insulin glargine, insulin detemir, insulin human (rDNa), HOE901, NN304, Lantus®, Levemir®, Insulatard®, Lantus®, Levemir®, Insulatard®
Klinisk Farmakologisk Center og Med. Afd. M, Århus Sygehus, NBG
Healthy subjects.
 
 
2005-003877-26: Comparison of the effect of insulin detemir and NPH insulin on dawn phenomenon in patients with Type 1 diabetes An open-labelled, randomised, cross-over, multi-center trial comparing the effect of insulin detemir versus NPH insulin as basal insulins on dawn phenomenon and the glycaemic control in patients with Type 1 diabetes treated on a basal-bolus regimen

Ongoing
4
100
Europe
Levemir, NovoRapid Penfill, Insulatard Penfill, Levemir, NovoRapid Penfill, Insulatard Penfill
National Centre for Diabetes Care, 1st Dept. Medicine, Diabetes Unit
Type 1 diabetes mellitus, dawn phenomenon
 
 
2005-002997-31: A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis.

Ongoing
4
40
Europe
Levemir Penfill,
Sheffield Children\'s NHS Trust
Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. Early treatment with insulin before diabetes develops may improve weight gain and lung function and delay progression to overt diabetes.
 
 
2006-002047-92: A multicentre, open-label, randomized comparison of once daily insulin detemir given pre-breakfast or bedtime, according to need, with bedtime insulin glargine in people with type 2 diabetes characterized by an asymmetric insulin requirement between the day and night.

Ongoing
4
74
Europe
Levemir FlexPen, Lantus OptiSet, Levemir FlexPen, Lantus OptiSet
Newcastle Primary Care Trust
Diabetes Mellitus
 
 
2006-005175-18: Influence of insulin Levemir on endothelial function in type 2 diabetes mellitus. A prospective case-control study.

Ongoing
4
75
Europe
Levemir (tradename), Levemir, Levemir
Dpt. of Internal Medicine, Medical University of Innsbruck
Patients with known history of type 2 Diabetes Mellitus longer than 6 months, who were treated by diet in combination with oral antidiabetic drugs (OADs) are to be included in the study.
 
 
2007-002773-30: Subcutaneous insulin therapy of hyperglycemia after initiation of oral intake in the ICU

Ongoing
4
50
Europe
NovoRapid, Levemir, NovoRapid, Levemir, NovoRapid, Levemir
Herz-, Thorax- und Gefäßchirurgische Anästhesie und Intensivmedizin
Hyperglycemia is very common in hospitalized, critically ill patients and is associated with higher mortality and morbidity. Careful monitoring and therapy of hyperglycemia have become standard in the ICU. Therapy of hyperglycemia by subcutaneously applied insulin after initiation of oral intake in the ICU is going to be investigated.
 
 
2007-004144-74: A comparison of the effects of insulin Detemir with insulin Glargine on weight gain in female adolescents and young adults with Type 1 Diabetes (T1D) on a basal bolus regime

Ongoing
4
125
Europe
Levemir Flexpen, Lantus 100 U/ml OptiSet solution for injection, Lantus 100u/ml solution for injection in Solostar prefilled pen, Levemir Flexpen, Lantus 100 U/ml OptiSet solution for injection, Lantus 100u/ml solution for injection in Solostar prefilled pen
Cambridge University Hospitals NHS Foundation Trust
Type 1 diabetes
 
 
2007-003085-17: The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes.

Ongoing
4
30
Europe
Levemir, Insulatard, NovoRapid, Levemir, Insulatard, NovoRapid
University of Surrey
Type 2 Diabetes Mellitus
 
 
2011-001642-14`ACTRN12621000158864: The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes

Ongoing
4
16
Europe
Detemir (Levemir®), NPH insulin (Insulatard®), Actrapid, EU/1/04/278/005, EU/1/02/233/003, Actrapid 100 IU/ml EU/1/02/230/003, Insulin detemir, Human insulin NPH insulatard, Insulin actrapid, Insulin detemir, Human insulin NPH insulatard, Insulin actrapid
University of Surrey, Flinders University
Obstructive sleep apnoea
 
 
2013-004737-33: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM Etude prospective randomisée multicentrique d’évaluation de la VILDagliptine associée à l’insuline sur le contrôle glycémique chez les patients hémoDIALysés diabétiques de type 2 : étude VILDDIAL

Not yet recruiting
4
70
Europe
Vildagliptine, Tablet, Solution for injection, Suspension for injection, Galvus, LANTUS 100 unités/ml solution injectable, LANTUS 100 unités/ml solution injectable en cartouche, LANTUS 100 unités/ml solution injectable en cartouche pour OptiClik, Lantus OptiSet 100 unités/ml solution injectable en stylo prérempli, Lantus SoloStar 100 unités/ml solution injectable en stylo prérempli, Levemir 100 U/ml, solution injectable en cartouche, Levemir 100 U/ml, solution injectable en stylo prérempli, Levemir InnoLet 100 U/ml, solution injectable en stylo prérempli, Levemir FlexTouch 100 U/ml, solution injectable en stylo prérempli, Apidra 100 unités/ml solution injectable en flacon, Apidra 100 unités/ml solution injectable en cartouche, Apidra 100 unités/ml solution injectable en cartouche pour OptiClik, Apidra 100 unités/ml solution injectable en stylo prérempli, Apidra SoloStar 100 unités/ml solution injectable en stylo prérempli, Humalog 100 UI/ml, solution injectable en flacon, Humalog 100 UI/ml, solution injectable en cartouche, Humalog Mix25 100 UI/ml suspension injectable en flacon, Humalog Mix25 100 UI/ml suspension injectable en cartouche, Humalog Mix50 100 UI/ml suspension injectable en flacon, Humalog Mix50 100 UI/ml suspension injectable en cartouche, Humalog BASAL 100 UI/ml suspension injectable en cartouche, Humalog Pen 100 UI/ml, solution injectable, Humalog Mix25 100 UI/ml Pen, suspension injectable, Humalog Mix50 100 UI/ml Pen, suspension injectable, Humalog BASAL 100 UI/ml Pen, suspension injectable, Humalog 100 UI/ml KwikPen, solution injectable, Humalog Mix25 100 UI/ml KwikPen, suspension injectable, Humalog Mix50 100 UI/ml KwikPen, suspension injectable, Humalog BASAL 100 UI/ml KwikPen, suspension injectable, NovoRapid 100 U/ml, solution injectable, NovoRapid Penfill 100 U/ml, solution injectable en cartouche, NovoRapid FlexPen 100 U/ml, solution injectable en stylo prérempli, NovoRapid InnoLet 100 U/ml, solution injectable en stylo prérempli, NovoRapid FlexTouch 100 U/ml, solution injectable en stylo prérempli
Hôpitaux Universitaires de Strasbourg, HÔPITAUX UNIVERSITAIRES DE STRASBOURG, NOVARTIS PHARMASAS
haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2017-004454-42: An interventional study to arrest the progression of cognitive decline in diabetic patients at high risk of developing Alzheimer's disease by reducinghypoglycemic events (low blood glucose). Estudio de intervención para detener o frenar la progresión del deteriorocognitivo en pacientes diabéticos con alto riesgo de desarrollar enfermedadde Alzheimer mediante la disminución de las hipoglucemias (niveles deazúcar bajos).

Ongoing
4
188
Europe
GLARGINE, NPH, LANTUS, INSULATARD, Solution for injection in pre-filled pen, Tresiba, Levemir, Lantus, Insulatard
Vall d'Hebron Research Institute, Vall d'Hebron Research Institute
Cognitive decline in patients affected with mild cognitive impairment Se investiga la progresión del deterioro cognitivo en pacientes con deterioro cognitivo incipiente, The progression of a condition named mild cognitive impairment (which antedates dementia) is investigated. Se investiga la progresión del deterioro cognitivo incipiente, que es una condición que antecede a la demencia., Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR1900027613: The Efficacy and Safety of Once-daily Insulin Degludec versus Twice-daily Long-acting Insulin in Adult Type 1 Diabetes Mellitus

Not yet recruiting
4
60
 
Insulin glargine or Insulin detemir for 3 months + Insulin Degludec for 3 months ;Insulin Degludec for 6 months
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-raised funds
Type 1 Diabetes
 
 
ChiCTR2100042914: The efficacy and safety of twice-a-day Insulin degludec /insulin aspart compared with the traditional intensive treatment regimen of four times a day in newly diagnosed type 2 diabetes mellitus

Recruiting
4
400
 
Insulin degludec/Insulin aspart therapy ;insulin detemir combined Insulin aspart therapy
Xichang People's Hospital; Xichang People's Hospital, Unit self-raised
diabetes
 
 
ChiCTR2400080751: A randomized, controlled trial to evaluate the improvement of oxidative stress levels and renal function in patients with diabetic kidney disease treated with semaglutide for 28 weeks

Completed
4
30
 
Insulin detemir; Semaglutide
Chu Hsien-I Memorial Hospital of Tianjin Medical University; Chu Hsien-I Memorial Hospital of Tianjin Medical University, Chu Hsien-I Memorial Hospital of Tianjin Medical University
Diabetic kidney disease
 
 
NCT04416269: Oral Anti Diabetic Agents in the Hospital

Recruiting
4
260
US
Oral Anti-diabetes Drugs alone, metformin, sulfonylureas, pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, Basal bolus insulin, glargine, detemir, Supplemental insulin, Humalog, Novolog, Continuous glucose monitoring (CGM), Dexcom
Emory University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus
11/24
12/24
2010-024024-14: INVESTIGACION DE LA OBESIDAD EN LAS INCRETINAS:EVALUACIÓN DE NUEVOS TRATAMIENTOS DE DIABETES.EFECTO DE LOS TRATAMIENTOS CON INSULINA, LIRAGLUTIDE Y CIRUGÍA BARIÁTRICA EN LA MEJORIA DE LA DIABETES TIPO II EN PACIENTES CON OBESIDAD GRADO I

Ongoing
3
150
Europe
VICTOZA 6 mg/ml solución inyectable en pluma precargada, DIANBEN 850 mg comprimidos recubiertos con película, LEVEMIR 100 U/ml, solución inyectable en una pluma precargada, VICTOZA 6 mg/ml solución inyectable en pluma precargada, DIANBEN 850 mg comprimidos recubiertos con película, LEVEMIR 100 U/ml, solución inyectable en una pluma precargada
CAIBER
DIABETES MELLITUS TIPO II (DMTII)
 
 
2010-022246-25: Diagnostic clinique et mécanismes physiopathologiques de l'allergie à l'insuline.

Not yet recruiting
3
70
Europe
Actrapid, Insulatard, Insuman Infusat, Humalog, NovoRapid, Apidra, Lantus, Levemir, Latex, Solution for injection, Suspension for injection, Solution for infusion, Actrapid, Insulatard, Novorapid, Levemir
Allergie à l'insuline
 
 
2016-001401-16: The SUGAR-DIP trial: Oral medication versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie versus insuline voor zwangerschapsdiabetes

Ongoing
3
810
Europe
Metformin, Glibenclamide, Tablet, Injection, Metformin, Glibenclamide, Insulin: including - fast acting, analog: NovoRapid, Humalog, Apidra - short acting, human: Actrapid, Humuline Regular, Insuman Rapid - medium long acting, human: Insulatard, Humuline NPH, Insuman Basal - long acting analog: Lantus, Levemir
University Medical Center Utrecht, ZonMw
The medical condition to be investigated in this trial is gestational diabetes with insufficient glycemic control by means of dietary adjustments and thus an indication for addiotional pharmacological treatment. In deze trial wordt het ziektebeeld diabetes gravidarum onderzocht, waarbij er met dieetaanpassingen onvoldoende glucosecontrole is bereikt en er dus indicatie is voor aanvullende farmacologische behandeling., Gestational diabetes, also known as gestational diabetes mellitus, is a condition in which women without previously diagnosed diabetes exhibit high blood glucose (blood sugar) levels during pregnancy. Zwangerschapssuikerziekte, ook wel zwangerschapsdiabetes, is een aandoening waarbij vrouwen waarbij niet al eerder suikerziekte is vastgesteld, tijdens de zwangerschap hoge bloedsuikerwaardes hebben., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
CF-IDEA, NCT01100892: Cystic Fibrosis - Insulin Deficiency, Early Action

Completed
3
100
US, RoW
Once-daily insulin detemir, Levemir
Sydney Children's Hospitals Network, John Hunter Children's Hospital, Lady Cilento Children's Hospital, Brisbane, Women's and Children's Hospital, Adelaide, Children's Hospital Colorado
Cystic Fibrosis, Diabetes
02/23
02/23
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
09/24
04/25
ACTRN12611000068965: CF-IDEA (Cystic Fibrosis - Insulin Deficiency, Early Action): Randomised controlled trial of once-daily insulin detemir in patients with cystic fibrosis and early insulin deficiency

Active, not recruiting
2/3
100
 
Sydney Children's Hospital, Australian Cystic Fibrosis Research Trust, National Health and Medical Research Council (NHMRC)
Cystic Fibrosis, Insulin Deficiency
 
 
2012-001208-39: A new therapeutic approach to prevent acute complications in type 2 diabetes: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® against the cOnventional insulin therapy: GALILEO Neuer Therapieansatz zur Verhinderung akuter Komplikationen bei Typ 2 Diabetes: Der Effekt einer Kombination des GLP-1 Analogons Liraglutide mit Insulin LEvemir im Vergleich zur kOnventionellen Insulintherapie: GALILEO

Ongoing
2
32
Europe
Insulin Levemir, Victoza, insulin aspart, EMEA/H/C/000528, EMEA/H/C/001026, EMEA/H/C/000308, Injection
Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel, Medizinische Universität Wien
diabetes mellitus type 2, inadequate metabolic control, indication for insulin therapymyocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-function, endothelial dysfunction Diabetes mellitus Typ 2,unzureichende Stoffwechselkontrolle, Indikation für InsulintherapieMyokardiale Lipidakkumualtion und Herzfunktion, retinale Veränderungen, Mikroalbuminurie, Beta-Zell-Funktion, Ednotheliale Dysfunktion, Typ 2 Diabetes, bad metabolic control, need for insulin therapyacute secondary diabetes-related complications Typ 2 Diabetes, schlechte Stoffwechseleinstellung, insulinpflichtigakute Folgeerkrankungen, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2011-003335-63: Effects of liraglutide on pancreatic function in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. Effetti di liraglutide sulla funzione pancreatica nei pazienti con diabete tipo 2 in fallimento secondario agli ipoglicemizzanti orali.

Ongoing
2
80
Europe
Solution for injection, Tablet, Coated tablet, VICTOZA*SC 2PEN 3ML 6MG/ML, GLIMEPIRIDE TEVA*20CPR 4MG, LEVEMIR*FLEX 5PEN 3ML 100UI/ML, METFORMINA TEVA IT*60CPR RIV1G
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, UNIVERSITA' DI PISA, NOVO NORDISK
Type 2 Diabetes mellitus Diabete mellito tipo 2, Type 2 Diabetes Diabete tipo 2, Diseases [C] - Hormonal diseases [C19]
 
 
2005-004754-27: Comparison of insulin detemir and insulin glargine in patients with Type 2 diabetes

Ongoing
2
12
Europe
insulin glargine, insulin detemir, Lantus 100 IU/ml, Levemir 100 U/ml, Lantus 100 IU/ml, Levemir 100 U/ml
Cardiff University
Type 2 Diabetes
 
 
2008-005263-34: The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY) 3. A 2 year, single-centre, open-label, randomised, parallel-group trial comparing insulin therapy to conventional oral sulphonyurea on beta-cell survival.

Ongoing
2
40
Europe
Diamicron, NovoRapid, Levemir, Diamicron, NovoRapid, Levemir, Diamicron, NovoRapid, Levemir
The Mater Foundation/HRB Grant
The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY ) 3.
 
 
DETERMINE, NCT05124457: Detemir vs NPH

Recruiting
2
336
US
Insulin Detemir, Insulin NPH
University of California, Los Angeles
Gestational Diabetes, Diabetes Mellitus, Type 2
06/25
06/25
IDIOM, NCT01239550: Insulin Detemir in Obesity Management

Active, not recruiting
N/A
240
US
Detemir, Levemir
Vanderbilt University, Novo Nordisk A/S
Diabetes, Obesity
12/25
12/25
NCT04965051: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Recruiting
N/A
40
RoW
insulin degludec/insulin aspart (IDegAsp), Ryzodeg, basal insulin plus pre-prandial insulin, Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra
Second Affiliated Hospital, School of Medicine, Zhejiang University
Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
12/23
12/23
START2, NCT06419803: Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

Not yet recruiting
N/A
430
US
Insulin, Lantus, Lispro, NPH, Levemir, Humalog
Thomas Jefferson University, University of Rochester
Gestational Diabetes, Pregnancy Related
05/26
05/26
START 1, NCT06419777: Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

Not yet recruiting
N/A
430
US
Insulin, Lantus, Lispro, NPH, Levemir, Humalog
Thomas Jefferson University, University of Rochester
Gestational Diabetes, Pregnancy Related
05/26
05/26

Download Options